BioXcel Initiates Strategic Big Data Partnership With Pronutria
Collaboration to Utilize Big Data Innovation Lab to Support Development of Novel Regenerative Biologics
BRANFORD, Conn., Oct. 20, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced the initiation of a strategic big data collaboration with Pronutria Biosciences to identify diseases characterized by high unmet need for therapies and nutritional products that are amenable to Pronutria's novel technology platform. Pronutria is a biotechnology company pioneering a new class of products to mediate amino acid biology. Through this partnership, Pronutria will utilize BioXcel's first-in-class Big Data Innovation Lab (BDI-Lab) to develop biologics that leverage its novel platform and amino acid-based approach. BDI-Lab is an integrated product discovery engine which applies big data algorithms, recursive mapping and network pharmacology to build associations and neural networks for deciphering novel treatment options for rare diseases with no current standard of care.
"With a proprietary platform of over 1 billion protein and fragment sequences to identify disease specific product candidates, we are unlocking the regenerative potential of homeostatic amino acid biology to transform the lives of patients and their families," said Dr. Peter Mueller, President of R&D and Chief Scientific Officer at Pronutria Biosciences. "By combining the potential of our proprietary platform with BioXcel's unique big data analytics and discovery capabilities, we will be able to enrich our pipeline with transformative products for relevant therapeutic and nutritional modalities."
"We are pleased to partner with Pronutria to utilize the disruptive capabilities of our Big Data Innovation Lab and Orphan Disease Suite to work toward the discovery and development of novel products targeting areas of high unmet need. Our lab capitalizes on multiple proprietary innovations and algorithms designed to trigger underlying metadata and analyses of over 9000 rare and ultra-rare diseases to identify novel product opportunities with transformative and life-saving potential," said BioXcel's Chief Executive Officer and Chairman, Vimal Mehta, Ph.D. "We are proud to be at the forefront of technology-powered pharma and biotech R&D. We believe that partnerships such as this will enable BioXcel to further establish its leadership position in this emerging scientific field and, more importantly, contribute to the discovery of novel treatments with the ability to significantly improve patients' lives."
Big Data Innovation Lab (BDI-Lab)
Our BDI-Lab is built on three key pillars – PharmGPSTM, a live cloud-based big data analytics platform built on proprietary algorithms and predictive analytics, multi-disciplinary teams of researchers based in our Integrated Center of Xcellence and a highly experienced and therapeutically aligned drug development team. Our live and multi-dimensional PharmGPSTM platform leverages BioXcel's proprietary Orphan Disease Suite that encompasses more than 9,000 rare and ultra-rare diseases, 4,000-5,000 associated genes, 1,500 disease pathways, and distinct target-indication tiles for antibody, protein, RNA, small molecule and gene therapy modalities. Partners can make informed decisions related to rare disease indications, and associate the ideal mode of pharmacotherapy, factoring in strategic, medical, scientific and commercial considerations. The suite enables the commercialization of orphan drugs via de novo drug discovery, or repurposing and reformulation of clinical assets (drug rescue) based on disease severity, gene ontology, disease pathways, proteinopathy, standard of care, emerging innovation, enabling technologies, and current drug pipeline – all of which are crucial when addressing the high unmet need of patients with rare and ultra rare diseases.
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS™ - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
CONTACT: BioXcel Corporation Anita Ganjoo Corporate Communications Email: firstname.lastname@example.org Tel: 203 957 2487Source: BioXcel Corporation
Released October 20, 2015